Please join Xilio Therapeutics for a virtual program spotlight on XTX101: A Novel, Fc-Enhanced, Tumor-Activated anti-CTLA-4, featuring expert oncologist/hematologist Diwakar Davar, MBBS, M.Sc (UPMC Hillman Cancer Center), who will discuss advancements in the understanding of CTLA-4, its interplay with CD28 and the opportunity associated with T-reg depletion, particularly in cold tumors like Microsatellite Stable Colorectal Cancer (MSS CRC).

René Russo, Chief Executive Officer, Marty Huber, President and Head of R&D, Katarina Luptakova, SVP, Clinical Research and Uli Bialucha, Chief Scientific Officer of Xilio, will discuss the company’s clinical-stage molecule, XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 designed to drive potent ADCC against T-regs that highly express CTLA-4 when activated (unmasked) in the tumor microenvironment (TME). The discussion will highlight monotherapy data from the ongoing Phase 1 multi-center, open-label clinical trial, evaluating the safety and tolerability of XTX101 as well as the planned next stage of development in combination with atezolizumab.

A live question and answer session will follow.